This pioneering research, published in PLOS Medicine, meticulously quantifies the potential financial fallout from scaled-back global donor support, estimating an additional $7.5 billion in household costs annually in the 79 LMICs studied. These elevated costs encompass direct medical expenses, ancillary non-medical charges such as transportation and nutrition, and often overlooked but critical indirect costs — chiefly income lost during prolonged illness and treatment. Alarmingly, the World Health Organization’s End TB Strategy defines “catastrophic costs” as those exceeding 20% of household income, and the study projects that an additional four million households could cross this devastating threshold.

USAID historically accounted for roughly one-fifth of all international TB funding, playing an indispensable role in catalyzing and sustaining TB prevention and treatment initiatives globally. The Global Fund to Fight AIDS, TB, and Malaria, still a leading benefactor, provides over 75% of international TB financing, a substantial portion of which originates from the United States. Together, these agencies have been credited with preventing approximately 75 million TB deaths worldwide.

Between 2023 and 2024, positive strides were observed globally, including a near 2% decline in TB infection rates and a 3% reduction in mortality. Yet, these gains now face jeopardy with diminishing donor contributions. Should the worst-case scenario arise—where all international TB funding abruptly halts—the economic burden borne by households could escalate near $80 billion, a staggering surge that threatens not only public health achievements but could plunge millions into poverty.

The study utilizes sophisticated linked epidemiological and economic simulation models, incorporating a range of scenarios reflecting varying degrees of donor withdrawal. These scenarios include maintaining 2024 funding levels, removing USAID support alone, and successive combinations of USAID and Global Fund funding reductions, culminating in the total cessation of external financial aid. The models reveal a striking 32% increase in household TB-related costs in the worst-case context compared to pre-2025 levels, disproportionately impacting the poorest 20% of the population.

Dr. Portnoy highlights the multifaceted nature of TB-related household expenses. Direct medical costs, though sometimes subsidized, still burden families through diagnostic fees, consultations, and medications. Non-medical costs, often less visible, significantly include logistics such as transportation and temporary accommodation during treatment. More devastating are indirect costs — particularly lost earnings — as TB frequently incapacitates patients for prolonged periods.

The economic consequences of these costs are severe and far-reaching. Families often resort to depleting their savings, incurring debt, or liquidating assets to cover expenses. Such financial strain reverberates beyond immediate medical realms, hindering children’s education, undermining food security, and entrenching long-term economic instability within vulnerable communities.

While the study acknowledges limitations stemming from assumptions about the costs faced by untreated or undiagnosed patients and future healthcare dynamics, it robustly conveys the dire economic consequences of reduced international aid. Prior research, including a BUSPH study, already forecasts catastrophic health outcomes from funding cuts, predicting an additional 9 million pediatric TB cases and 1.5 million child deaths linked to the withdrawal of US support alone.

Faced with the prospect of dwindling global financial backing, the study authors emphasize the imperative for LMICs to fortify domestic health financing mechanisms and enhance primary healthcare system integration for TB services. Innovative financial protection strategies—ranging from direct cash transfers to subsidized transportation and social protection schemes—must be scaled up to counterbalance the indirect economic shocks of TB illness and therapy.

Crucially, donor withdrawal strategies require careful calibration. Sudden funding terminations can destabilize national TB programs, potentially reversing hard-won public health progress. Instead, phased, coordinated transitions incorporating blended finance models—combining governmental funding, private sector involvement, and targeted donor assistance—offer a pragmatic pathway to sustain TB control efforts amidst shifting fiscal landscapes.

As the global health community approaches World TB Day on March 24, this study serves as a clarion call: restoring and reinforcing international support for TB programs is essential not only to safeguard public health but also to alleviate the profound financial hardships faced by millions of vulnerable families worldwide. Sustained donor investment, coupled with strategic domestic reforms and innovative financing, is critical to realizing the promise of the End TB Strategy and ending the tuberculosis epidemic.

Subject of Research: People

Article Title: The potential impact of reduced international donor funding on the household economic burden of tuberculosis in low- and middle-income countries: A modeling study

News Publication Date: 20-Feb-2026

Web References:

• PLOS Medicine article
• WHO End TB Strategy
• Global gains in Tuberculosis response (WHO)

References:
Portnoy A. et al., “The potential impact of reduced international donor funding on the household economic burden of tuberculosis in low- and middle-income countries: A modeling study,” PLOS Medicine, February 2026.

Keywords: Tuberculosis, Respiratory disorders, Infectious diseases, Public health, Epidemics, Medical economics, Health care industry, Health care costs, Drug costs, Economics

Tuberculosis, a disease deeply intertwined with socioeconomic determinants of health, imposes complex financial implications on patients and households beyond the biological impacts of the infection itself. The costs incurred from TB care extend far beyond the direct medical expenses. Patients often face indirect costs such as transportation to health facilities, lost wages due to illness, nutritional supplements, and other associated expenditures. In low- and middle-income countries such as India, these costs can be catastrophic, often pushing already impoverished households deeper into economic distress. The study systematically quantifies these costs and uncovers how they are distributed across income quintiles, revealing persistent inequities and exposing systemic vulnerabilities.

The researchers approached the analysis through a large-scale, nationally representative sample, meticulously assessing TB care costs by stratifying the affected population into five income quintiles. This stratification allowed for a nuanced understanding of how economic burdens vary by income and for identifying particular groups that bear disproportionate financial stress. The findings show that while TB affects all income groups, the catastrophic financial impact is most severe among the poorest quintiles, where even modest TB care expenses can constitute a significant share of household income.

The methodological rigor of their approach included comprehensive data collection on both direct and indirect cost components associated with TB diagnosis, treatment initiation, follow-up visits, and drug procurement. They also factored in the duration of illness and treatment adherence, which often extends over several months, further exacerbating financial strain. The cumulative data underscore that TB care costs frequently exceed 10% of annual household income for those in the lower-income brackets, a threshold widely recognized as catastrophic health expenditure due to its potential to destabilize household economics.

Importantly, the study highlights a paradox within India’s healthcare financing landscape. Despite the existence of government-sponsored TB control programs intended to offer free diagnosis and treatment, patients incur significant out-of-pocket expenses driven by factors such as unavailability of drugs, reliance on private healthcare providers, and geographic barriers to accessing public services. This incongruity underscores gaps between policy implementation and real-world scenarios, which perpetuate financial inequities and dilute the effectiveness of free care initiatives.

The economic consequences of TB care costs transcend immediate healthcare-related spending. For poorer households facing catastrophic costs, the repercussions ripple across multiple facets of life, including child education, food security, and asset sustainability. The study elucidates that catastrophic TB-related expenditures often force families into asset liquidation, borrowing at high interest rates, and nutritional compromises, all of which contribute to a vicious cycle of poverty and disease that hampers recovery and long-term socioeconomic mobility.

Researchers also discuss the implications of these findings in the context of India’s ambitious goals to eliminate TB by 2030, as outlined by the National Tuberculosis Elimination Programme (NTEP) and aligned with the United Nations Sustainable Development Goals (SDGs). The financial barriers unearthed by this study represent critical obstacles to universal access to care and adherence to treatment regimens, both of which are essential to curbing transmission and preventing drug resistance.

The study’s revelations call attention to the urgent need for policy reforms that go beyond simply providing free medicines and diagnostics. The authors advocate for comprehensive social protection frameworks tailored to the needs of the most vulnerable groups. Such frameworks could include cash transfers, transportation subsidies, nutritional support, and other financial safety nets designed specifically to offset the hidden costs of TB care. Implementing these measures could significantly reduce the burden on marginalized populations, enabling better health outcomes and fostering equity.

Furthermore, by mapping out the inequities in catastrophic costs across income quintiles, the study provides an empirical basis for targeted interventions that maximize resource efficiency. Prioritizing support for the poorest income groups can lead to a more equitable health system and amplify the impact of TB control efforts nationwide. This approach aligns with principles of health equity and social justice, emphasizing that disease control cannot be fully effective without simultaneously addressing socioeconomic determinants.

This research also underscores a broader challenge faced by many low- and middle-income countries battling infectious diseases: the interplay between health system limitations and persistent socioeconomic inequalities creates conditions that allow disease-associated poverty traps to thrive. The Indian context, with its vast population heterogeneity and stark income disparities, exemplifies this challenge. Addressing the catastrophic costs of TB care hence requires integrated policies combining health, social welfare, and economic development.

Technically, the study used robust statistical models to estimate the proportion of households experiencing catastrophic costs and employed sensitivity analyses to test the solidity of their findings under various assumptions. This technical rigor ensures the reliability of their conclusions and provides actionable data for policymakers and healthcare planners. The differentiation of costs into direct medical, direct non-medical, and indirect categories enriches the dataset, enabling a granular understanding of cost drivers and intervention points.

The implications of this research extend beyond national borders. TB, designated as a global health emergency by the World Health Organization, disproportionately impacts impoverished settings worldwide. Insights from the Indian context offer valuable lessons for other countries grappling with similar socioeconomic gradients in disease burden and health financing. In particular, the findings reinforce the necessity of integrating financial risk protection mechanisms into global TB elimination strategies.

In conclusion, the work of Jeyashree and colleagues is a pivotal contribution to global health literature, illuminating the often-overlooked financial dimensions of TB care and their inequitable distribution across socioeconomic strata in India. Their findings warrant immediate attention from health policymakers, international donors, and social welfare advocates. Scaling up social protection interventions and ensuring the inclusion of cost-alleviating measures within TB programs will be critical for breaking the cycle of poverty and disease, moving India closer to the goal of ending TB as a public health threat.

As the fight against TB intensifies globally, this study acts as a clarion call to remember that eradicating infectious diseases is as much about equitable economic policies as it is about medical innovation. Investing in comprehensive financial risk mitigation for TB patients can unlock better adherence, reduce transmission, and ultimately save lives — creating healthier, more resilient societies.

—

Subject of Research: Cost and equity analysis of tuberculosis care expenditures in India, focusing on the distribution of catastrophic TB-related costs across different income quintiles.

Article Title: Cost of TB care and equity in distribution of catastrophic TB care costs across income quintiles in India

Article References:

Jeyashree, K., Thangaraj, J.W.V., Shanmugasundaram, D. et al. Cost of TB care and equity in distribution of catastrophic TB care costs across income quintiles in India.
glob health res policy 9, 51 (2024). https://doi.org/10.1186/s41256-024-00392-9

Image Credits: AI Generated

The study highlights that the predominant drivers of these financial hurdles include hospitalization and the significant loss of income during lengthy treatment regimes. While global health initiatives have successfully increased access to TB care, the associated financial demands remain a critical barrier that affects patients’ adherence to treatment, their overall health outcomes, and the healthcare system at large. Despite the best intentions of free treatment programs, the reality on the ground is far more complex and heartbreaking.

Patients from low-, middle-, and high-income settings face unique challenges as they navigate their TB treatment. In high-income countries, while the immediate costs of treatment may be covered, indirect costs such as lost wages and additional medical bills can accumulate and wreak havoc on a family’s finances. Conversely, in low- and middle-income countries, where the healthcare infrastructure may be less robust, not only are the direct costs of care prohibitively high, but the social and economic ramifications of TB can be devastating.

The emotional and psychological toll on TB patients is another dimension that cannot be overlooked. The exhaustion wrought by prolonged illness, coupled with the financial stress of treatment, often results in feelings of hopelessness and despair. Patients described their experiences as isolating, pushing them to the brink as they grappled with societal stigma and the burdens of household responsibilities that are exacerbated due to their condition.

Research shows that loss of income during treatment periods is significant, particularly for those supporting their families through informal work within their communities. Patients reported being unable to work for prolonged periods, leading to a downward spiral of debt and socioeconomic decline. Such circumstances highlight a critical gap in health policy concerning TB, where economic support systems are inadequately aligned with patient care paradigms.

This systematic review not only sheds light on the financial implications of TB but also prompts a call to action for policymakers. There is an evident need to design comprehensive support systems that consider both direct medical expenses and indirect costs such as lost productivity. If healthcare systems can address the multifaceted dimensions of TB care, including financial support for patients, they may see improvements in treatment adherence and clinical outcomes.

Furthermore, the systemic issues underlying the catastrophic costs associated with TB are often reflective of broader socioeconomic inequities. Individuals in marginalized communities face disproportionate burdens related to poverty, lack of access to healthcare, and inadequate social safety nets. Tackling these inequities requires a holistic approach that combines health policies with socioeconomic initiatives.

The urgency for greater awareness about these issues cannot be overstated. Studies like this serve as essential tools for educating the public and stakeholders about the real financial impact of diseases like TB. As more individuals become informed about the true costs of TB, there is hope to foster community support for affected families, advocating for policy changes that prioritize patient well-being over mere treatment metrics.

Moreover, international organizations and governments must work collaboratively to formulate strategies that mitigate these catastrophic costs. Understanding the financial landscape that patients navigate through can help direct resources toward innovative solutions, such as financial stipends or compensation for lost wages during treatment. Ultimately, providing comprehensive care should encompass more than just the medical facets; it must also embrace the economic realities of patients’ lives.

As we look to the future, the impact of education and destigmatization regarding TB must remain a priority. By fostering dialogue around the financial implications of TB care, we can help break down barriers that prevent individuals from seeking treatment, thereby increasing early detection rates and reducing transmission within communities.

The commitment to tackling TB extends far beyond healthcare systems; it requires a societal movement that uplifts affected individuals and fosters collaboration across multiple sectors. As new research emerges, stakeholders are urged to reflect on the lived experiences of TB patients, paving a path towards a more equitable health landscape.

With the publication of this study in PLOS Global Public Health, we are reminded that significant work remains to ensure that TB patients do not face insurmountable financial challenges in the quest for care. By advocating for better support systems and broader socioeconomic reforms, the global community stands a better chance at eradicating TB as a public health threat.

The fight against TB is not solely a medical battle; it is a shared responsibility to address the underlying inequities that perpetuate suffering. As awareness grows around the catastrophic costs of TB care, there is hope that change will be enacted, transforming the narrative from one of despair to one of resilience and recovery.

Subject of Research: Catastrophic Costs of TB Care
Article Title: The catastrophic cost of TB care: Understanding costs incurred by individuals undergoing TB care in low-, middle-, and high-income settings – A systematic review
News Publication Date: April 2, 2025
Web References: 10.1371/journal.pgph.0004283
References: N/A
Image Credits: Smiley N. Pool (2016)

Keywords: Tuberculosis, healthcare costs, financial barriers, socioeconomic equity, patient support, public health policy.